Meeder Asset Management »

Rapport Therapeutics shares owned by Meeder Asset Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Meeder Asset Management from 13F filings

Historical chart of Meeder Asset Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Meeder Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Meeder Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $37k 1.2k 30.34

More positions owned by Meeder Asset Management

Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Alphabet Cap Stk Cl C (GOOG)
Apple (AAPL)
Berkshire Hathaway Inc Del Cl B New (BRK.B)
Ishares Tr 7-10 Yr Trsy Bd (IEF)
Meta Platforms Cl A (META)
Ishares Tr Jpmorgan Usd Emg (EMB)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
General Dynamics Corporation (GD)
Mastercard Incorporated Cl A (MA)
Bank of New York Mellon Corporation (BK)
Eli Lilly & Co. (LLY)
State Street Corporation (STT)
Johnson & Johnson (JNJ)

View all positions for Meeder Asset Management

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
BlackRock
Sofinnova Ventures
Vanguard Group
Johnson & Johnson
Baker Bros. Advisors
Vestal Point Capital
Polar Capital Holdings
Trv Gp Vi
Ubs Global Asset Management Americas

View all funds holding Rapport Therapeutics